Trials / Completed
CompletedNCT04773964
Study to Evaluate MET642 in Patients With NASH
Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Metacrine, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MET642 | MET642 active treatment |
| DRUG | Placebo | Placebo comparator |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2021-02-26
- Last updated
- 2024-03-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04773964. Inclusion in this directory is not an endorsement.